Developer of wearable health monitors and metabolic glucose tracking devices. These products track sleep, recovery, and metabolic markers to provide...
Total Rounds: 11 Ultrahuman
| S.No. | Date | Round Name | Amount | TTM Revenue | Investors & Facilitators |
|---|---|---|---|---|---|
| 1. | Sep 3, 2026 | Venture Debt | ₹47 Cr | ₹2,490 Cr | Inst: Alteria Capital |
| 2. | Sep 1, 2026 | Series C | ₹617 Cr | ₹2,490 Cr | Inst: Qualcomm Ventures, Alpha Wave Global, Steadview, Blume Venture, LabCorp, Ggm Family Trust, Nexus Venture Partners, Krypton Angel: Deepinder |
| 3. | Mar 17, 2026 | Series C | ₹443 Cr | ₹2,490 Cr | - |
| 4. | Nov 20, 2025 | Venture Debt | ₹100 Cr | ₹1,854 Cr | Inst: Alteria Capital |
| 5. | Nov 3, 2025 | Series B | ₹3.2 Cr | ₹1,854 Cr | Inst: Alteria Capital |
| 6. | Nov 2025 | Venture Debt | ₹100 Cr | ₹108 Cr | Inst: Alteria Capital |
| 7. | Mar 20, 2024 | Conventional Debt | ₹83 Cr | ₹108 Cr | Inst: Blume Venture, Steadview, Nexus Venture Partners, Alpha Wave Global Angel: Deepinder |
| 8. | Mar 14, 2024 | Series B | ₹207 Cr | ₹108 Cr | Inst: Blume Venture, Steadview, Nexus Venture Partners, Alpha Wave Global Angel: Deepinder |
| 9. | Mar 30, 2023 | Series A | ₹38 Cr | ₹30 Cr | Inst: Nexus Venture Partners, Blume Venture, Steadview, Avant Garde Ventures, Panthera Capital Ventures Angel: Balaji, Nithin, Preethi, Ishan, Neeraj, Harshil, Lalit, Harsh, Shashank, Akshay, Tanmay, Deepinder, Bhuvan |
| 10. | Aug 14, 2021 | Series A | ₹130 Cr | ₹4.3 Cr | Inst: Nexus Venture Partners, Blume Venture, iSeed, Steadview, Alpha Wave Global, Utsav Somani, SAB Holding, QED Innovation Labs, Angel List Angel: Sandeep, Sujeet, Deepinder, Kunal, Mohit, Gunjan, Scott, Vikram, Gaurav, Revant, Roman, Kumud |
| 11. | Dec 11, 2019 | Seed | ₹55 Cr | - | Inst: Nexus Venture Partners, Blume Venture Angel: Adit Pankaj Parekh, Nishith, Gaurav |
| Detailed Income Statement | FY 24-25 (in Cr) |
|---|---|
| 580.8 | |
| 535.1 | |
| Total profit before exceptional items, extraordinary items and tax | 45.7 |
| Total profit before tax | 45.7 |
| (27.3) | |
| Total profit (loss) for period from continuing operations | 73.0 |
| Total profit (loss) for period | 73.0 |
| Basic earning per equity share | 0.0 |
| Diluted earnings per equity share | 0.0 |
| Detailed Balance Sheet | FY 24-25 (in Cr) |
|---|---|
| 618.2 | |
| 618.2 |
| Detailed Cash Flow Statement | FY 24-25 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (37.0) |
| Net cash from / (used in) investing activities | 24.8 |
| Net cash from / (used) in financing activities | 13.5 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | 1.3 |
| Effect of exchange rate changes on cash and cash equivalents | 0.8 |
| Net increase / (decrease) in cash and cash equivalents | 2.0 |
| Cash and cash equivalents at the beginning of the year | 73.1 |
| Cash and cash equivalents at the end of the year | 75.1 |
| Detailed Income Statement | FY 23-24 (in Cr) |
|---|---|
| 108.4 | |
| 146.4 | |
| Total profit before exceptional items, extraordinary items and tax | (38.0) |
| Total profit before tax | (38.0) |
| 0 | |
| Total profit (loss) for period from continuing operations | (38.0) |
| Total profit (loss) for period | (38.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 23-24 (in Cr) |
|---|---|
| 315.3 | |
| 315.3 |
| Detailed Cash Flow Statement | FY 23-24 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (53.3) |
| Net cash from / (used in) investing activities | (128.1) |
| Net cash from / (used) in financing activities | 208.8 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | 27.4 |
| Effect of exchange rate changes on cash and cash equivalents | 0 |
| Net increase / (decrease) in cash and cash equivalents | 27.4 |
| Cash and cash equivalents at the beginning of the year | 45.7 |
| Cash and cash equivalents at the end of the year | 73.1 |
| Detailed Income Statement | FY 22-23 (in Cr) |
|---|---|
| 30.1 | |
| 101.2 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (71.2) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (71.2) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (71.2) |
| 0 | |
| Total profit (loss) for period from continuing operations | (71.2) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Profit (loss) of minority interest | 0 |
| Share of profit (loss) of associates | 0 |
| Total profit (loss) for period | (71.2) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 22-23 (in Cr) |
|---|---|
| 114.8 | |
| 114.8 |
| Detailed Cash Flow Statement | FY 22-23 (in Cr) |
|---|
| Detailed Income Statement | FY 21-22 (in Cr) |
|---|---|
| 7.4 | |
| 65.1 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (57.8) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (57.8) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (57.8) |
| 0 | |
| Total profit (loss) for period from continuing operations | (57.8) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (57.8) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 21-22 (in Cr) |
|---|---|
| 123.1 | |
| 123.1 |
| Detailed Cash Flow Statement | FY 21-22 (in Cr) |
|---|
| Detailed Income Statement | FY 20-21 (in Cr) |
|---|---|
| 2.1 | |
| 25.3 | |
| Total profit before prior period items, exceptional items, extraordinary items and tax | (23.2) |
| Exceptional items before tax | 0 |
| Total profit before extraordinary items and tax | (23.2) |
| Extraordinary items before tax | 0 |
| Total profit before tax | (23.2) |
| 0 | |
| Total profit (loss) for period from continuing operations | (23.2) |
| Profit (loss) from discontinuing operations before tax | 0 |
| Tax expense of discontinuing operations | 0 |
| Total profit (loss) from discontinuing operation after tax | 0 |
| Total profit (loss) for period | (23.2) |
| Basic earning per equity share before extraordinary items | (0.0) |
| Diluted earnings per equity share before extraordinary items | (0.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 20-21 (in Cr) |
|---|---|
| 36.6 | |
| 36.6 |
| Detailed Cash Flow Statement | FY 20-21 (in Cr) |
|---|
| Detailed Income Statement | FY 19-20 (in Cr) |
|---|---|
| 0.6 | |
| 3.7 | |
| Profit before exceptional items and tax | 0 |
| Total profit before tax | (3.1) |
| 0 | |
| Total profit (loss) for period from continuing operations | (3.1) |
| Detailed Balance Sheet | FY 19-20 (in Cr) |
|---|---|
| 40.7 | |
| 40.7 |
| Detailed Cash Flow Statement | FY 19-20 (in Cr) |
|---|
As of May 16, 2026 • Ultrahuman
| Shareholder | Category | Shares (Mn) | % Holding |
|---|---|---|---|
| Mohit Kumar | Other | 0.01M | 21.29% |
| Nexus Ventures V Ltd | Other | 0.01M | 18.13% |
| Vatsal Singhal | Other | 0.00M | 9.12% |
| Steadview Capital Mauritius Limited | Other | 0.00M | 5.09% |
| Deepinder Goyal | Other | 0.00M | 1.85% |
